FAM193B

Across TCGA pan-cancer cohorts, FAM193B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FAM193B data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FAM193B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM193B expression acts as an unfavorable survival marker.

LUAD, BLCA, and STAD are the cancer types where FAM193B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.004	0.835	<.001	36	view →
BLCA	DFS	Median	All	0.156	0.627	.004	18	view →
STAD	OS	Median	II,III,IV	0.501	0.660	.006	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FAM193B–LUAD (OS)

Open the LUAD breakdown →